Cancer Research Cell Death Mechanisms and Cancer Therapy Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kulkarni, S.
Right arrow Articles by Cross, N. C. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kulkarni, S.
Right arrow Articles by Cross, N. C. P.
[Cancer Research 60, 3592-3598, July 1, 2000]
© 2000 American Association for Cancer Research

Molecular Biology and Genetics

Fusion of H4/D10S170 to the Platelet-derived Growth Factor Receptor ß in BCR-ABL-negative Myeloproliferative Disorders with a t(5;10)(q33;q21)1

Shashikant Kulkarni, Carol Heath, Sally Parker, Andrew Chase, Sameena Iqbal, Christopher F. Pocock, Jaspal Kaeda, Kate Cwynarski, John M. Goldman and Nicholas C. P. Cross2

Department of Haematology, Imperial College School of Medicine Hammersmith Hospital, London W12 0NN, United Kingdom


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
We have studied a patient who presented with clinical features suggestive of chronic myeloid leukemia in accelerated phase. BCR-ABL transcripts were undetectable by reverse transcription-PCR, but a novel reciprocal translocation, t(5;10)(q33;q21.2), was seen by standard cytogenetic analysis. Chromosome band 5q33 contains the gene encoding the platelet-derived growth factor ß receptor (PDGFßR), the receptor tyrosine kinase that is disrupted by the t(5;7), t(5;12), and t(5;14) in myeloid disorders, resulting in the fusion of PDGFßR to HIP1, TEL/ETV6, and CEV14, respectively. Southern analysis with PDGFßR cDNA revealed novel bands in patient but not control DNA after digestion with several restriction enzymes, indicating that this gene is also targeted by the t(5;10). Fluorescence in situ hybridization analysis of chromosome 5 indicated that a small inversion at 5q33 had taken place in addition to the interchromosomal translocation. The site of the chromosome 10 breakpoint fell within YAC 940e4. Because all PDGFßR fusions described thus far result in splicing to a common exon of this gene, we performed 5'-rapid amplification of cDNA ends PCR on patient RNA. Several clones were isolated in which PDGFßR fused in frame to H4/D10S170, a previously described ubiquitously expressed gene that is fused to the ret protein tyrosine kinase to form the PTC-1 oncogene in approximately 20% of papillary thyroid carcinomas. The presence of H4-PDGFßR chimeric mRNA in the patient was confirmed by reverse transcription-PCR; reciprocal PDGFßR-H4 transcripts were not detected. We conclude that t(5;10)(q33;q21.2) is a novel translocation in BCR-ABL-negative chronic myeloid leukemia and that this abnormality results in an H4-PDGFßR fusion gene. This finding further strengthens the association between myeloproliferative disorders and deregulated tyrosine kinases.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
In approximately 95% of cases, leukocytes from patients with CML3 are characterized by the presence of the BCR-ABL fusion gene, which is usually visible cytogenetically as the t(9;22)(q34;q11). The remaining 5% of patients have no evidence of either the t(9;22) or BCR-ABL. Whereas a small number of these cases appear to be indistinguishable from BCR-ABL-positive patients in terms of clinical and laboratory findings, the majority present with atypical, heterogeneous clinical features and have a relatively poor prognosis compared with BCR-ABL-positive cases. The precise classification of these aCML patients is the subject of some controversy, but it is generally held that aCML comprises part of a spectrum of MPDs and MDSs that includes CMML, polycythemia rubra vera, essential thrombocythemia, idiopathic myelofibrosis, and other cases with minimal or no granulocytic dysplasia that have usually been diagnosed as having an unclassifiable, atypical, or BCR-ABL-negative MPD (1, 2, 3) .

The molecular pathogenesis of aCML, CMML, and other BCR-ABL-negative MPDs is poorly understood, principally because most cases present with a normal karyotype or have only numerical chromosomal changes. However, occasional patients are characterized by the presence of an acquired reciprocal chromosomal translocation. At the molecular level, almost all of these translocations that have been cloned thus far result in the disruption and constitutive activation of protein tyrosine kinases such as ABL, JAK2, PDGFßR, or FGFR1 (4, 5, 6, 7, 8) . The molecular definition of additional cases will not only lead to a better understanding of this heterogeneous group of diseases but is also likely to lead to the recognition of novel, discrete clinical entities such as the 8p11 myeloproliferative syndrome, which is specifically associated with translocations that disrupt FGFR1 (8 , 9) .

Here we describe a patient with a BCR-ABL-negative MPD who presented with a t(5;10)(q33;q21.2) and clinical features suggestive of CML in accelerated phase. We have cloned this translocation and demonstrated that it results in the fusion of a known gene, H4/D10S170, to PDGFßR. This is the fourth translocation involving PDGFßR described thus far, and our findings strengthen the association between deregulated tyrosine kinases and MPDs.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Patient Material.
Patient PD, a 48-year-old man, presented with severe upper abdominal pain. This was preceded by a 6-month history of left upper quadrant and widespread skeletal pain, weight loss, and easy bruising. Clinical examination revealed massive splenomegaly palpable 20 cm below the left costal margin. The blood count showed 114 g/liter hemoglobin, a WBC count of 94 x 109/liter, and 70 x 109/liter platelets. The blood film showed a leukoerythroblastic picture with teardrop poikilocytes. The proportion of eosinophils was elevated at 7%, but there was no increase in blasts, monocytes, or basophils. Attempts at bone marrow aspiration yielded a dry tap. The bone marrow trephine showed granulocytic hyperplasia, established myelofibrosis (grade III-IV reticulin), and no evidence of blastic transformation. Karyotypic analysis on peripheral blood showed the presence of a t(5;10)(q33;q21.2); BCR-ABL transcripts were not detected by multiplex RT-PCR (10) . A diagnosis of BCR-ABL-negative MPD (with some clinical features of CML in accelerated phase) was made, and the patient commenced on hydroxyurea with good control of symptoms. He subsequently underwent splenectomy (histology of the spleen revealed red pulp consistent with extramedullary hemopoiesis) and allogeneic bone marrow transplantation from his HLA-identical sister.

FISH.
YAC clones were obtained from the Medical Research Council Human Genome Mapping Project Resource Center (Hinxton, United Kingdom). Cosmids 9-4, 14C2, and 4-1 were provided by Dr. P. Marynen (Center for Human Genetics, University of Lueven, Leuven, Belgium). YAC and cosmid DNA was isolated by standard procedures and labeled with biotin by nick translation. After testing on metaphases from phytohemagglutinin-stimulated peripheral blood lymphocytes from a normal individual, labeled probes were hybridized to patient metaphases as described previously (11) . In some cases, probes were cohybridized with a Cy3-labeled chromosome 10 painting probe (Cambio, Cambridge, United Kingdom). Hybridization signals were detected using FITC avidin (Vector, Peterborough, United Kingdom). Chromosomes were counterstained with 4',6-diamidino-2-phenylindole/antifade (Biovation, Aberdeen, United Kingdom) and examined using an Olympus Vanox microscope. Images were captured using a charge-coupled device camera and SmartCapture Software (Vysis, Richmond, United Kingdom).

RACE PCR.
RNA was extracted from fresh peripheral blood mononuclear cells using the RNeasy Mini system (Qiagen, Hilden, Germany). 5'-RACE PCR was performed using a commercial kit (Life Technologies, Inc., Paisley, United Kingdom) according to the manufacturer’s instructions. Briefly, 2 µg of patient RNA were reverse-transcribed using primer PDGFR-D and SuperScript reverse transcriptase. Excess nucleotides were removed by spin cartridge purification, and the cDNA was dC-tailed using terminal deoxytransferase. Tailed cDNA was amplified by a two-step heminested PCR using primers AAP + PDGFR-F in the first step and primers AAP + PDGFR-C in the second step, with 30 cycles for each reaction. Amplified products were cloned using an Original TA Cloning Kit (Invitrogen, Leek, the Netherlands) and sequenced.

RT-PCR and Southern Analysis.
Patient RNA and control RNA were reverse-transcribed as described previously (10) . All primer sequences are given in Table 1Citation . Restriction enzyme digestion and Southern blot analysis were performed under standard conditions. A PDGFßR cDNA probe (provided by Dr. A. Chantry, Imperial College School of Medicine, London, United Kingdom) that spanned the predicted breakpoint region was amplified from a full-length cDNA clone using primers PDGFR-D and PDGFR-E and gel-purified. Control DNA and RNA were extracted from patients with typical BCR-ABL-positive CML.


View this table:
[in this window]
[in a new window]

  		Table 1 Primer sequences

 

   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Initial Karyotypic and Molecular Analysis.
Standard cytogenetic analysis on peripheral blood showed that 16 of 24 metaphases harbored a t(5;10)(q33;q21.2), whereas the remaining 8 metaphases were normal. Multiplex RT-PCR analysis revealed an absence of BCR-ABL transcripts, thus excluding a diagnosis of CML (data not shown).

Southern Analysis of Chromosome 5.
Chromosome band 5q33 contains PDGFßR, the receptor tyrosine kinase that is a target of the t(5;7), t(5;12), and t(5;14) in myeloid disorders (6 , 12 , 13) . To determine whether this gene might also be disrupted by the t(5;10), we performed Southern analysis with a PDGFßR cDNA probe. Novel rearranged bands were seen in patient but not control DNA after digestion with several restriction enzymes (Fig. 1)Citation , indicating that this gene is indeed targeted by the t(5;10).



View larger version (89K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Southern blot of patient and control DNA probed with PDGFßR cDNA. Rearranged bands in the patient with a t(5;10) are indicated by an asterisk.

 
FISH Analysis of Chromosome 5.
Unexpectedly, cosmids 14C2 and 4-1, which contain the 3' and 5' parts of the PDGFßR locus, respectively,4 each hybridized to the der(5) and not to the der(10) (Fig. 2)Citation . If a simple reciprocal translocation had taken place, it would have been anticipated that either one cosmid would hybridize to both derivative chromosomes or that 14C2 would hybridize to the der(5) , and 4-1 would hybridize to the der(10) . YACs 745d10 and 756a2, which flank but do not contain PDGFßR (14) , also both hybridized to the der(5) and not the der(10) . Further analysis demonstrated that YAC 816d6, which is further distal to PDGFßR (15) , hybridized to both the der(10) and the der(5) , whereas YAC 850c10 hybridized to the der(10) only. This suggested that a complex rearrangement had taken place, with the first event having been a translocation between the region spanned by YAC 816d6 and chromosome 10, and the second event having been an inversion on the der(5) resulting in a fusion of H4 and PDGFßR (Fig. 3A)Citation . This is likely to have taken place as a single event involving four chromosomal breaks (Fig. 3B)Citation . This model predicts that YAC 756a2 should lie in between cosmids 9-4 and 4-1 on the der(5) but be distal to the two cosmids on normal chromosome 5. These orders were confirmed by fiber FISH: on normal copies of chromosome 5, the YAC 756a2 signal was seen to partially overlap with the two cosmids, whereas on the der(5) , YAC 756a2 is flanked by cosmid signals (Fig. 2, E and F)Citation . It is likely that YAC 756a6 is also partially deleted on the der(5) because the signal from this clone consistently and almost completely overlapped with the cosmid signals. Complex rearrangements appear to be a common feature of rare translocations that in many cases appear karyotypically to be straightforward genetic exchanges, for example, the ZNF198-FGFR1, TEL-ABL, and AF10-MLL fusions that result from the t(8;13), t(9;12), and t(10;11), respectively (Ref. 8 and the references therein). The data presented here serve as an illustration that FISH analysis may give misleading results in the analysis of chromosomal translocations. In this case, for example, FISH analysis alone would have suggested that PDGFßR was not involved in the t(5;10).



View larger version (74K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. FISH analysis. A-D, YAC or cosmid signals are shown in green, and chromosome 10 sequences are highlighted by a red painting probe. Hybridization signals are seen on the following chromosomes: YAC 745d10 (A), normal chromosome 5 and der(5); YAC 756a2 (B), normal chromosome 5 and der(5); YAC 816d6 (C), normal chromosome 5, der(5), and der(10); YAC 940e4 (D), normal chromosome 10, der(5), and der(10). E and F, fiber FISH on normal chromosome 5 and the der(5) in t(5;10) cells, respectively. YAC 756a2 is labeled in green, and both cosmids 9-4 and 4-1 are labeled in red.

 


View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. A, the t(5;10) is a complex rearrangement: (i), order of clones on chromosome 5 and summary of FISH results; (ii), hypothetical intermediate der(5) resulting from a translocation between the region spanned by YAC 816d6 and chromosome 10; (iii), final der(5) resulting from an inversion on the intermediate der(5) that produces the fusion H4-PDGFßR. B, schematic model of the formation of the t(5;10): (i), initial juxtaposition of chromosomes 5 and 10; (ii), pattern of four-way breakage and rejoining; (iii), resolved der(5) and der(10).

 
FISH Analysis of Chromosome 10.
To determine the site of breakage on chromosome 10, FISH was performed with an ordered series of YAC clones that were known to map to 10q11–22. On patient metaphases, YACs 794g4, 942d3, 845g11, 916d5, and 928d9 hybridized to the der(10) , whereas YACs 954a2, 948h12, and 750h4 hybridized to the der(5) . All clones hybridized to normal chromosome 10, and some also hybridized to other chromosomes in some cases due to chimerism. These data indicated a breakpoint between YACs 928d9 and 954a2 in the vicinity of marker D10S207 (15) . Subsequent analysis showed that YAC 940e4 hybridized to both derivative chromosomes and therefore spanned the chromosome 10 breakpoint (Figs. 1CCitation and 4)Citation .



View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Summary of FISH results for chromosome 10. The positions of YAC clones and anonymous DNA markers are shown. The translocation breakpoint is in the vicinity of D10S207.

 
RACE PCR.
All cases that have been analyzed thus far with a t(5;7), t(5;12), or t(5;14) result in the fusion of distinct partner genes to a common exon of PDGFßR (6 , 12 , 13) . To determine whether the t(5;10) resulted in a novel fusion gene, we used 5'-RACE PCR using primers within or downstream of this common PDGFßR exon. Several clones were isolated in which the sequence diverged from PDGFßR at precisely the same point as that seen in the other three translocations. A BLAST search revealed that the novel sequence was derived from a known gene, H4/D10S170 (16) . PCR analysis demonstrated that this gene was contained in YAC 940e4 (not shown).

RT-PCR.
To confirm the presence of chimeric mRNA in patient leukocytes, we performed RT-PCR analysis. H4-PDGFßR chimeric mRNA was detected specifically in the patient RNA but not in control RNA (Fig. 5)Citation . Reciprocal PDGFßR-H4 transcripts were not detected. The break in H4 occurred between positions 1141 and 1142 of the cDNA sequence (GenBank accession number S72869) and resulted in an in-frame fusion to PDGFßR. The H4-PDGFßR fusion gene is predicted to encode a Mr 107,000 protein of 948 amino acids that contains the leucine zipper from H4 and the entire transmembrane and tyrosine kinase domains of PDGFßR (Fig. 6)Citation .



View larger version (55K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. RT-PCR analysis. H4-PDGFßR chimeric transcripts were detected in the patient with the t(5;10) but not in two normal individuals or in two patients with CML. The reciprocal PDGFßR-H4 fusion was not detected. H4 transcripts were found in all individuals.

 


View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6. A, schematic representation of the H4-PDGFßR fusion protein showing the leucine zipper from H4 plus the transmembrane (TM) and split tyrosine kinase domains of PDGFßR. B, sequences surrounding the H4-PDGFßR cDNA breakpoint.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Chromosomal translocations that target specific non-receptor and receptor tyrosine kinases are seen frequently in hematological malignancies (Table 2)Citation and in all cases result in the NH2-terminal fusion of a partner gene to the COOH-terminal catalytic domain of the tyrosine kinase. The resulting chimeric gene is transcribed and translated into a fusion protein. Functional analysis has demonstrated that many of these chimeric proteins, such as BCR-ABL, TEL-JAK2, and ZNF198-FGFR1, possess transforming activity as a result of the constitutive activation of their tyrosine kinase moieties (17, 18, 19) . Constitutive activity arises by partner gene-dependent oligomerization of fusion proteins and thus mimics the normal process of tyrosine kinase signaling after binding of their cognate ligands (19 , 20) . In addition, the partner gene may relocalize the tyrosine kinase to a different cellular compartment from that in which it normally resides, thus potentially enabling the kinase to phosphorylate novel substrates. It is particularly striking that deregulated tyrosine kinases are involved in virtually all cases of MPD for which the underlying pathogenesis is known, including the case described here.


View this table:
[in this window]
[in a new window]

  		Table 2 Deregulated tyrosine kinases in hematological disorders

 
We have identified H4 as the fourth partner gene that becomes fused to PDGFßR as a result of chromosomal translocation, with the other three being HIP1, TEL/ETV6, and CEV14 (Table 2)Citation . Recently, we have become aware of an additional case with a t(5;10) and H4-PDGFßR fusion, indicating that this abnormality is recurrent (21) . Of these four fusions, the TEL-PDGFßR and HIP1-PDGFßR chimeric proteins have been shown to possess constitutive tyrosine kinase activity and transforming ability (12 , 22) ; it is highly likely that this is the case for the other two fusions as well.

H4 is a widely expressed gene that is fused to ret as a result of an inv(10) (q22q21) in a subset of papillary thyroid carcinomas (23 , 24) . The H4-ret fusion protein, usually referred to as PTC-1, is a constitutively active tyrosine kinase. Transgenic mice with thyroid-targeted expression of PTC-1 developed thyroid carcinomas, indicating that this fusion plays a primary role in the pathogenesis of the disease with which it is associated (25) . H4 is not the only gene that is disrupted in both solid tumors and hematological malignancies: for example, TPM3, which encodes a nonmuscular tropomyosin, is fused to ALK in anaplastic large cell lymphoma with a t(1;2) and TRK in a subset of papillary thyroid carcinomas (26) . Furthermore, the ETV6-TRKC fusion has been described in both patients with congenital fibrosarcoma and patients with acute myeloid leukemia (27 , 28) .

H4 shows weak but significant homology to the myosin superfamily, but its normal function is unclear. H4 contains a NH2-terminal leucine zipper that mediates dimerization of PTC-1 and is essential for the constitutive activation of its tyrosine kinase (29) . This leucine zipper is also present in H4-PDGFßR. In addition, the H4 promoter drives the expression of constitutively active ret in thyroid follicular cells, a tissue in which it is not usually expressed. The mechanism of transformation by H4-PDGFßR is presumably similar, except that in this case, H4 is driving constitutive PDGFßR tyrosine kinase activity in primitive hemopoietic cells.

It has been recognized for several years that the t(5;12) is associated with an unusual MPD/MDS that is difficult to classify within defined French-American-British subtypes (30, 31, 32) . Specifically, patients typically present with eosinophilia plus other clinical features that are suggestive of both CML and CMML. Very similar clinical pictures were seen in other patients who had diseases characterized by primary deregulation of PDGFßR, e.g., those associated with the t(5;7) or the t(5;10). The fourth fusion, CEV14-PDGFßR, was different in that it arose as a secondary abnormality at relapse in a patient who presented initially with AML and a t(7;11). However, it is notable that the acquisition of the t(5;14) was associated with the appearance of marked eosinophilia and hepatosplenomegaly, i.e., features usually associated with a MPD (33) . Remarkably, and at the current time, inexplicably, all 27 cases that have been reported with a MPD/MDS and a t(5;12), t(5;7), or t(5;10) have been male (12 , 21 , 31) . Taken together, these observations suggest that primary deregulation of PDGFßR leads to a consistent phenotype, which might be better designated as a specific clinical subtype.


   ACKNOWLEDGMENTS
 
We thank Dr. Tom Vulliamy for invaluable advice, Dr. Andrew Chantry for providing the PDGFßR cDNA clone, and Dr. Peter Marynen for providing the PDGFßR cosmid clones.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by Leukaemia Research Fund Specialist Programme Grant 97/19. Back

2 To whom requests for reprints should be addressed, at Department of Haematology, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom. Phone: 44-20-8383-3302; Fax: 44-20-8740-9679; E-mail: n.cross{at}ic.ac.uk Back

3 The abbreviations used are: CML, chronic myeloid leukemia; aCML, atypical CML; RT-PCR, reverse transcription-PCR; PDGFßR, platelet-derived growth factor ß receptor; FISH, fluorescence in situ hybridization; RACE, rapid amplification of cDNA ends; MPD, myeloproliferative disorder; MDS, myelodysplastic syndrome; CMML, chronic myelomonocytic leukemia; YAC, yeast artificial chromosome; AML, acute myeloid leukemia. Back

4 P. Marynen, personal communication. Back

Received 2/ 7/00. Accepted 5/ 3/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H., Sultan C., Cox C. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br. J. Haematol., 87: 746-754, 1994.[Medline]
  2. Martiat P., Michaux J. L., Rodhain J. Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Francais de Cytogenetique Hematologique. Blood, 78: 205-211, 1991.[Abstract/Free Full Text]
  3. Oscier D. G. Atypical chronic myeloid leukaemia, a distinct clinical entity related to the myelodysplastic syndrome?. Br. J. Haematol., 92: 582-586, 1996.[Medline]
  4. Papadopoulos P., Ridge S. A., Boucher C. A., Stocking C., Wiedemann L. M. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res., 55: 34-38, 1995.[Abstract/Free Full Text]
  5. Peeters P., Raynaud S. D., Cools J., Wlodarska I., Grosgeorge J., Philip P., Monpoux F., Van Rompaey L., Baens M., Van den Berghe H., Marynen P. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood, 90: 2535-2540, 1997.[Abstract/Free Full Text]
  6. Golub T. R., Barker G. F., Lovett M., Gilliland D. G. Fusion of PDGF receptor ß to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell, 77: 307-316, 1994.[Medline]
  7. Smedley D., Hamoudi R., Clark J., Warren W., Abdul Rauf M., Somers G., Venter D., Fagan K., Cooper C., Shipley J. The t(8;13)(p11;q11–12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP. Hum. Mol. Genet., 7: 637-642, 1998.[Abstract/Free Full Text]
  8. Reiter A., Sohal J., Kulkarni S., Chase A., Macdonald D. H. C., Aguiar R. C. T., Goncalves C., Hernandez J. M., Jennings B. A., Goldman J. M., Cross N. C. P. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood, 92: 1735-1742, 1998.[Abstract/Free Full Text]
  9. Macdonald D., Aguiar R. C., Mason P. J., Goldman J. M., Cross N. C. P. A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. Leukemia (Baltimore), 9: 1628-1630, 1995.[Medline]
  10. Cross N. C. P., Melo J. V., Feng L., Goldman J. M. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in hematological disorders. Leukemia (Baltimore), 8: 186-189, 1994.[Medline]
  11. Aguiar R. C. T., Chase A., Coulthard S., Macdonald D. H., Carapeti M., Reiter A., Sohal J., Lennard A., Goldman J. M., Cross N. C. P. Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement. Blood, 90: 3130-3135, 1997.[Abstract/Free Full Text]
  12. Ross T. S., Bernard O. A., Berger R., Gilliland D. G. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor ß receptor (PDGFßR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood, 91: 4419-4426, 1998.[Abstract/Free Full Text]
  13. Abe A., Emi N., Tanimoto M., Terasaki H., Marunouchi T., Saito H. Fusion of the platelet-derived growth factor receptor ß to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood, 90: 4271-4277, 1997.[Abstract/Free Full Text]
  14. Wlodarska I., Aventin A., Ingles Esteve J., Falzetti D., Criel A., Cassiman J. J., Mecucci C., Van den Berghe H., Marynen P. A new subtype of pre-B acute lymphoblastic leukemia with t(5;12)(q31q33;p12), molecularly and cytogenetically distinct from t(5;12) in chronic myelomonocytic leukemia. Blood, 89: 1716-1722, 1997.[Abstract/Free Full Text]
  15. Dib C., Faure S., Fizames C., Samson D., Drouot N., Vignal A., Millasseau P., Marc S., Hazan J., Seboun E., Lathrop M., Gyapay G., Morissette J., Weissenbach J. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature (Lond.), 380: 152-154, 1996.[Medline]
  16. Grieco M., Cerrato A., Santoro M., Fusco A., Melillo R. M., Vecchio G. Cloning and characterization of H4 (D10S170), a gene involved in RET rearrangements in vivo. Oncogene, 9: 2531-2535, 1994.[Medline]
  17. Daley G. Q., Van Etten R. A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (Washington DC), 247: 824-830, 1990.[Abstract/Free Full Text]
  18. Schwaller J., Frantsve J., Aster J., Williams I. R., Tomasson M. H., Ross T. S., Peeters P., Van Rompaey L., Van Etten R. A., Ilaria R., Marynen P., Gilliland D. G. Transformation of hemtaopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J., 17: 5321-5333, 1998.[Medline]
  19. Smedley D., Demiroglu A., Abdul-Rauf M., Heath C., Cooper C., Shipley J., Cross N. C. P. ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATs 1 and 5. Neoplasia, 1: 349-355, 1999.[Medline]
  20. Golub T. R., Goga A., Barker G. F., Afar D. E., McLaughlin J., Bohlander S. K., Rowley J. D., Witte O. N., Gilliland D. G. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol. Cell. Biol., 16: 4107-4116, 1996.[Abstract]
  21. Anastasiadou E., Schwaller J., Sternberg D. W., Cain D., Grieco M., Siena S., Mecucci C., Gilliland D. G. H4(10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived ß receptor (PDGFßR) in atypical chronic myeloid leukemia with a t(5;10)(q33;q22). Blood, 94(Suppl.1): 51a 1999.
  22. Carroll M., Tomasson M. H., Barker G. F., Golub T. R., Gilliland D. G. The TEL/platelet-derived growth factor ß receptor (PDGFßR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFßR kinase-dependent signaling pathways. Proc. Natl. Acad. Sci. USA, 93: 14845-14850, 1996.[Abstract/Free Full Text]
  23. Grieco M., Santoro M., Berlingieri M. T., Melillo R. M., Donghi R., Bongarzone I., Pierotti M. A., Della Porta G., Fusco A., Vecchio G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell, 60: 557-563, 1990.[Medline]
  24. Pierotti M. A., Santoro M., Jenkins R. B., Sozzi G., Bongarzone I., Grieco M., Monzini N., Miozzo M., Herrmann M. A., Fusco A., Hay I. D., Dellaporta G., Vecchio G. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc. Natl. Acad. Sci. USA, 89: 1616-1620, 1992.[Abstract/Free Full Text]
  25. Jhiang S. M., Sagartz J. E., Tong Q., Parker Thornburg J., Capen C. C., Cho J. Y., Xing S., Ledent C. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology, 137: 375-378, 1996.[Abstract]
  26. Lamant L., Dastugue N., Pulford K., Delsol G., Mariame B. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood, 93: 3088-3095, 1999.[Abstract/Free Full Text]
  27. Knezevich S. R., McFadden D. E., Tao W., Lim J. F., Sorensen P. H. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat. Genet., 18: 184-187, 1998.[Medline]
  28. Eguchi M., Eguchi Ishimae M., Tojo A., Morishita K., Suzuki K., Sato Y., Kudoh S., Tanaka K., Setoyama M., Nagamura F., Asano S., Kamada N. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood, 93: 1355-1363, 1999.[Abstract/Free Full Text]
  29. Tong Q., Xing S., Jhiang S. M. Leucine zipper-mediated dimerization is essential for the PTC1 oncogenic activity. J. Biol. Chem., 272: 9043-9047, 1997.[Abstract/Free Full Text]
  30. Berkowicz M., Rosner E., Rechavi G., Mamon Z., Neuman Y., Ben Bassat I., Ramot B. Atypical chronic myelomonocytic leukemia with eosinophilia and translocation (5;12): a new association. Cancer Genet. Cytogenet., 51: 277-278, 1991.[Medline]
  31. Wessels J. W., Fibbe W. E., van der Keur D., Landegent J. E., van der Plas D. C., den Ottolander G. J., Roozendaal K. J., Beverstock G. C. t(5;12)(q31;p12): a clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemia. Cancer Genet. Cytogenet., 65: 7-11, 1993.[Medline]
  32. Bain B. J. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br. J. Haematol., 95: 2-9, 1996.[Medline]
  33. Abe A., Tanimoto M., Towatari M., Matsuoka A., Kitaori K., Kato H., Toyozumi H., Takeo T., Adachi K., Emi N., Kawashima K., Saito H. Acute myeloblastic leukemia (M2) with translocation (7;11) followed by marked eosinophilia and additional abnormalities of chromosome 5. Cancer Genet. Cytogenet., 83: 37-41, 1995.[Medline]
  34. Heisterkamp N., Stam K., Groffen J., de Klein A., Grosveld G. Structural organization of the bcr gene and its role in the Ph' translocation. Nature (Lond.), 315: 758-761, 1985.[Medline]
  35. Shtivelman E., Lifshitz B., Gale R. P., Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature (Lond.), 315: 550-554, 1985.[Medline]
  36. Andreasson P., Johansson B., Carlsson M., Jarlsfelt I., Fioretos T., Mitelman F., Hoglund M. BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion. Genes Chromosomes Cancer, 20: 299-304, 1997.[Medline]
  37. Lacronique V., Boureux A., Valle V. D., Poirel H., Quang C. T., Mauchauffe M., Berthou C., Lessard M., Berger R., Ghysdael J., Bernard O. A. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science (Washington DC), 278: 1309-1312, 1997.[Abstract/Free Full Text]
  38. Xiao S., Nalabolu S. R., Aster J. C., Ma J., Abruzzo L., Jaffe E. S., Stone R., Weissman S. M., Hudson T. J., Fletcher J. A. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat. Genet., 18: 84-87, 1998.[Medline]
  39. Popovici C., Adelaide J., Ollendorff V., Chaffanet M., Guasch G., Jacrot M., Leroux D., Birnbaum D., Pebusque M. J. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Proc. Natl. Acad. Sci. USA, 95: 5712-5717, 1998.[Abstract/Free Full Text]
  40. Popovici C., Zhang B., Gregoire M. J., Jonveaux P., Lafage Pochitaloff M., Birnbaum D., Pebusque M. J. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood, 93: 1381-1389, 1999.[Abstract/Free Full Text]
  41. Morris S. W., Kirstein M. N., Valentine M. B., Dittmer K. G., Shapiro D. N., Saltman D. L., Look A. T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science (Washington DC), 263: 1281-1284, 1994.[Abstract/Free Full Text]
  42. Hernández L., Pinyol M., Hernández S., Beà S., Pulford K., Rosenwald A., Lamant L., Falini B., Ott G., Mason D. Y., Delsol G., Campo E. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood, 94: 3265-3268, 1999.[Abstract/Free Full Text]
  43. Ma Z., Cools J., Marynen P., Cui X., Siebert R., Gesk S., Schlegelberger B., Peeters B., De Wolf-Peeters C., Wlodarska I., Morris S. W. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood, 95: 2144-2149, 2000.[Abstract/Free Full Text]
  44. Cazzaniga G., Tosi S., Aloisi A., Giudici G., Daniotti M., Pioltelli P., Kearney L., Biondi A. The tyrosine kinase Abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts. Blood, 94: 4370-4373, 1999.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 haematolHome page
C. Walz, G. Metzgeroth, C. Haferlach, A. Schmitt-Graeff, A. Fabarius, V. Hagen, O. Prummer, S. Rauh, R. Hehlmann, A. Hochhaus, et al.
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor {beta} gene
Haematologica, February 1, 2007; 92(2): 163 - 169.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
M. Santoro, R. M. Melillo, and A. Fusco
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.
Eur. J. Endocrinol., November 1, 2006; 155(5): 645 - 653.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Frohling, C. Scholl, D. G. Gilliland, and R. L. Levine
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
J. Clin. Oncol., September 10, 2005; 23(26): 6285 - 6295.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Delaval, S. Letard, H. Lelievre, V. Chevrier, L. Daviet, P. Dubreuil, and D. Birnbaum
Oncogenic Tyrosine Kinase of Malignant Hemopathy Targets the Centrosome
Cancer Res., August 15, 2005; 65(16): 7231 - 7240.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
A. Tefferi and D. G. Gilliland
The JAK2V617F Tyrosine Kinase Mutation in Myeloproliferative Disorders: Status Report and Immediate Implications for Disease Classification and Diagnosis
Mayo Clin. Proc., July 1, 2005; 80(7): 947 - 958.
[Abstract] [PDF]

Home page
 BloodHome page
M. Wadleigh, D. J. DeAngelo, J. D. Griffin, and R. M. Stone
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
Blood, January 1, 2005; 105(1): 22 - 30.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Pardanani and A. Tefferi
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders
Blood, October 1, 2004; 104(7): 1931 - 1939.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Morerio, M. Acquila, C. Rosanda, A. Rapella, C. Dufour, F. Locatelli, E. Maserati, F. Pasquali, and C. Panarello
HCMOGT-1 Is a Novel Fusion Partner to PDGFRB in Juvenile Myelomonocytic Leukemia with t(5;17)(q33;p11.2)
Cancer Res., April 15, 2004; 64(8): 2649 - 2651.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. L. Vizmanos, F. J. Novo, J. P. Roman, E. J. Baxter, I. Lahortiga, M. J. Larrayoz, M. D. Odero, P. Giraldo, M. J. Calasanz, and N. C. P. Cross
NIN, a Gene Encoding a CEP110-Like Centrosomal Protein, Is Fused to PDGFRB in a Patient with a t(5;14)(q33;q24) and an Imatinib-Responsive Myeloproliferative Disorder1
Cancer Res., April 15, 2004; 64(8): 2673 - 2676.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. L. Garcia, J. Font de Mora, J. M. Hernandez, J. A. Queizan, N. C. Gutierrez, J. M. Hernandez, and J. F. S. Miguel
Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta
Blood, October 1, 2003; 102(7): 2699 - 2700.
[Full Text] [PDF]

Home page
 BloodHome page
L. Oehler, E. Jaeger, A. Eser, C. Sillaber, H. Gisslinger, and K. Geissler
Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro
Blood, September 15, 2003; 102(6): 2240 - 2242.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. H. Griffin, J. Leung, R. J. Bruner, M. A. Caligiuri, and R. Briesewitz
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome
PNAS, June 24, 2003; 100(13): 7830 - 7835.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Sohal, V. T. Phan, P. V. Chan, E. M. Davis, B. Patel, L. M. Kelly, T. J. Abrams, A. M. O'Farrell, D. G. Gilliland, M. M. Le Beau, et al.
A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657
Blood, April 15, 2003; 101(8): 3188 - 3197.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. F. Apperley, M. Gardembas, J. V. Melo, R. Russell-Jones, B. J. Bain, E. J. Baxter, A. Chase, J. M. Chessells, M. Colombat, C. E. Dearden, et al.
Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta
N. Engl. J. Med., August 15, 2002; 347(7): 481 - 487.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. B. Dash, I. R. Williams, J. L. Kutok, M. H. Tomasson, E. Anastasiadou, K. Lindahl, S. Li, R. A. Van Etten, J. Borrow, D. Housman, et al.
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9
PNAS, May 28, 2002; 99(11): 7622 - 7627.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. M. Kelly, Q. Liu, J. L. Kutok, I. R. Williams, C. L. Boulton, and D. G. Gilliland
FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
Blood, January 1, 2002; 99(1): 310 - 318.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Demiroglu, E. J. Steer, C. Heath, K. Taylor, M. Bentley, S. L. Allen, P. Koduru, J. P. Brody, G. Hawson, R. Rodwell, et al.
The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins
Blood, December 15, 2001; 98(13): 3778 - 3783.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. K. Magnusson, K. E. Meade, K. E. Brown, D. C. Arthur, L. A. Krueger, A. J. Barrett, and C. E. Dunbar
Rabaptin-5 is a novel fusion partner to platelet-derived growth factor {beta} receptor in chronic myelomonocytic leukemia
Blood, October 15, 2001; 98(8): 2518 - 2525.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Schwaller, E. Anastasiadou, D. Cain, J. Kutok, S. Wojiski, I. R. Williams, R. LaStarza, B. Crescenzi, D. W. Sternberg, P. Andreasson, et al.
H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor {beta} gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22)
Blood, June 15, 2001; 97(12): 3910 - 3918.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kulkarni, S.
Right arrow Articles by Cross, N. C. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kulkarni, S.
Right arrow Articles by Cross, N. C. P.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online